Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/01/25
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase ProgramBusiness Wire • 05/01/25
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loomCNBC • 04/30/25
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYKZacks Investment Research • 04/30/25
Gear Up for DexCom (DXCM) Q1 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 04/29/25
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?Zacks Investment Research • 04/29/25
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffsCNBC • 04/16/25
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA ClearanceZacks Investment Research • 04/11/25
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US LaunchBenzinga • 04/10/25
Dexcom Surges After FDA Clears Its Next-Generation Diabetes DeviceInvestors Business Daily • 04/10/25
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM SystemBusiness Wire • 04/10/25
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.Business Wire • 04/03/25
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring SystemsBusiness Wire • 04/01/25
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond DiabetesZacks Investment Research • 03/31/25
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalZacks Investment Research • 03/27/25
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomBusiness Wire • 03/25/25
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does NextThe Motley Fool • 03/19/25